BRAF and melanoma: Previously, ‘driver-negative’ (i.e. the absence of BRAF, NRAS, KIT, GNAQ or GNA11 mutations) melanoma cell-lines that were less sensitive to trametinib and which displayed paradoxical activation of MEK1/2, were found to show basal EGFR activation due to AREG [52].